To the Editor: We found the letters from Drs. Eth and Wystanski challenging and worthy of thought and a reply. In general, the more discussion that is generated around issues related to informed consent in treatment and research, the better our field will become. Although our article did not address the component of consent on which Dr. Eth comments, our future research is pursuing this very avenue. Dr. Eth comments on the impact of transference in influencing the decision to participate in research. While they were undoubtedly true for our population, transference issues influence patients treated by other medical specialists as well. There is little difficulty, for example, in recruiting heart transplant patients for studies of medications to prevent rejection of their newly transplanted hearts. Patients who have undergone life-saving transplant surgeries will naturally be very willing participants in studies suggested to them by their surgeons. We scrutinize the ability of subjects with schizophrenia to give informed consent because they are generally perceived to be members of a vulnerable population. But are they in fact more vulnerable and therefore more exploited than other medical patients with incurable illnesses (e.g., AIDS, various malignancies, Alzheimer’s disease, Parkinson’s disease)?